Overview
GMAB market data
Price History
GMAB price chart · 1M
- O
- 34.93
- H
- 35.46
- L
- 34.71
- C
- 35.32
- Vol
- 220,552.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $34.93
- Previous Close
- $34.82
- Day High
- $35.46
- Day Low
- $34.71
- 52 Week High
- $35.66
- 52 Week Low
- $23.62
- 7 Day Return
- +1.70%
- 30 Day Return
- +4.65%
- 90 Day Return
- +35.77%
- 1 Year Return
- +34.07%
- Daily Notional Volume
- $7.8M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 26.45 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $15.36 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.75 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 19.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1,512.00 – $2,334.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $137B · P/B 3.25 · P/S 5.05.
Company News
10 captured
Grant of Restricted Stock Units and Warrants to Employees in GenmabGlobenewswire Inc ·
Capital Increase in Genmab as a Result of Employee Warrant ExerciseGlobenewswire Inc ·
Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsightGlobenewswire Inc ·